Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2021 16:08 ET | Source: Kura Oncology, Inc.

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS...